DIRS.INFO The most relevant business & tech news

☆ Ozempic, Mounjaro and hundreds of other drugs become even more expensive in 2024
▼ + stars: | 2024-02-15 | by ( Tami Luhby | ) edition.cnn.com time to read: +8 min

Novo Nordisk boosted the list price of Ozempic by 3.5% to $969 for a four-week supply. Eli Lilly last month raised the list price of Mounjaro by 4.5% to $1,069 for a four-week supply. However, they may have to pay the list price if they are uninsured or have not yet hit their annual deductible. Former President Donald Trump, who is running for election again, also unveiled several proposals and issued executive orders aimed at lowering drug costs during his administration. Another factor is the recent policies that penalize pharmaceutical manufacturers for raising list prices faster than inflation.

Persons: Drugmakers, Eli Lilly, Eli Lilly’s Zepbound, Ozempic, Eli Lily, Marlene Foss, Foss, “, ”, Mark Rapp, Rapp, ’ ”, Mark Rapp's, grandkids, ” Rapp, Joe Biden’s, Donald Trump, We’ve, Antonio Ciaccia, we’ve Organizations: New, New York CNN, Ozempic, Novo Nordisk, CNN, Food and Drug Administration, Nordisk’s, Mounjaro, Medicare, ”, White House Locations: New York, Portugal, Doylestown , Pennsylvania, Italy, Mansfield , Ohio, Ohio, Idaho

☆ Sitting on gains in Eli Lilly, Nvidia? Ask these questions before your next move
▼ + stars: | 2024-02-09 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +10 min

Eli Lilly has jumped almost 27%, building on its 59% gain in 2023. The long-term outlooks for Nvidia and Eli Lilly — both longtime Club holdings — brightened in recent weeks, leading to additional gains for the stocks. This leaves Club members who own Nvidia, Eli Lilly, or both, wondering how to proceed with their investments. Right now, we feel good about the timing of our most recent sales in Nvidia and Eli Lilly. Eli Lilly's stock is currently up about 24% from our Sept. 12 sale level, based on Thursday's close.

Persons: Eli Lily, Eli Lilly, Eli Lilly —, Eli Lilly's, Zepbound, Lilly's, Jim Cramer, Jim, There's, they're, Colette Kress, Goldman Sachs, FactSet, Lilly, Novo, Nordisk's Wegovy, tirzepatide, Jim Cramer's Organizations: Nvidia, Club, Apple, Microsoft, Web Services, Nordisk's, CNBC, Reuters Locations: Wall

☆ Monthly Meeting Q&A with Jim Cramer on 20 stocks in everything from tech to industrials to drugs
▼ + stars: | 2023-11-16 | by ( Paulina Likos | ) www.cnbc.com time to read: +12 min

(Anthony) Jim Cramer: There were some China statistics that showed that the consumer was doing slightly better. (David) Jim Cramer: The roadblock is that the money is at the state level. (Narayan) Jim Cramer: " Own, don't trade" is about trying to keep us in a stock that otherwise we would trade out of. (Jim) Jim Cramer: First, I think we have to remember Ford actually has a lot of money on its balance sheet — a lot of cash. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

Persons: Jim Cramer's, Jeff Marks, Estee Lauder, Anthony, Jim Cramer, Wynn, It's, David, I'm, Narayan, it's, Steve Jobs, John, Tom Jorden, That's, Capex, Paul, Procter, Jim Farley, Jim, Ford, Shawn Fain, Farley, Donald, Larry Culp, He's, GEHC, Eli Lily, Louis, Lilly, Zepbound, We've, Alzheimer's, tirzepatide, hasn't, Edmundo, we've, haven't, Linde, Theresa, Jim Cramer Rob Kim Organizations: Investing Club, Club, Caterpillar, Amazon, Nvidia, Apple, Web Services, Natural Resources, Exxon, Procter, Gamble, United Auto Workers, GE Healthcare, Electric, GE, General, Merck, Drug Administration, Novo Nordisk, Linde, LIN, Trust, Barrick, CNBC Locations: China, reaccelerate, GEHC

☆ Obesity drug Wegovy's landmark trial result could 'open up' health insurance access, analyst says
▼ + stars: | 2023-08-09 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +6 min

Until now, some health insurers have been reluctant to cover the drug, given its high costs and a lack of data around its underlying health benefits. But the results of the latest trial data could change that. "Do I think most payers will adopt [obesity drugs] overnight because of the SELECT trial? According to the World Health Organization, global obesity rates have almost tripled over the past decade. Novo Nordisk shares soared by 17% following the release of the trial results on Tuesday.

Persons: Jim Vondruska, Peter Verdult, CNBC's, Wegovy, Verdult, Martin Holst Lange, Eli Lilly, Mounjaro, Michael Mason, Eli Lily, Lilly Diabetes, It's, Lilly, Novo, Lily Organizations: Reuters LONDON, Novo Nordisk, Citi, Novo, World Health Organization, Barclays, Citi Verdult, European Markets Authority Locations: Chicago , Illinois, Danish, U.S, Europe, London

☆ Weight loss drug Wegovy is from Europe — but users in the region face a long and costly wait
▼ + stars: | 2023-07-26 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +3 min

Packages of the weight-loss drug Wegovy from the pharmaceutical company Novo Nordisk lie on the sales counter in a Danish pharmacy. Still, it's seen as too expensive for many public health systems in Europe. They're obviously in a capacity constrained environment and we don't know how much they're willing to allocate to Europe. Eli Lily , whose diabetes drug Mounjaro can also be used for weight loss, has also faced supply gluts. They're obviously in a capacity constrained environment and we don't know how much they're willing to allocate to Europe," Field said.

Persons: Stefan Trumpf, it's, Emily Field, Wegovy's, Eli Lily Organizations: Novo Nordisk, Getty, CNBC, Denmark — Novo, Barclays, BMI, German Obesity Society, Novo Nordisk — Locations: Danish, Germany, Europe, Denmark, Norway, Novo, U.S

☆ Jim Cramer's top 10 things to watch in the market Tuesday: Wages too high, China reopening
▼ + stars: | 2023-01-03 | by ( Jim Cramer | ) www.cnbc.com time to read: +5 min

Barclays raises price target on Club holding Eli Lily (LLY) by $5-per-share to $400. UBS downgrades PG & E (PCG) to neutral from buy, with a $17-per-share price target; just above where the stock closed Friday. Barclays raises Exxon Mobil (XOM) price target to $129 per share from $111; keeps overweight (buy) rating. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

☆ Twitter Blue relaunches, now costs $11 per month if you subscribe from an iPhone
▼ + stars: | 2022-12-12 | by ( Ashley Capoot | ) www.cnbc.com time to read: +3 min

Twitter relaunched its updated Twitter Blue subscription service Monday after the company's new owner Elon Musk pulled and delayed the launch in November. The service costs $8 a month for web users and $11 a month for iOS users who purchase it through Apple 's App Store. Blue users will also be able to edit tweets and get early access to new features. Twitter Blue briefly launched in November, but it was pulled after users abused the new paid option by impersonating celebrities and brands. Users who were verified under Twitter's old policy are being marked as legacy verified accounts that "may not be notable" under the new Twitter Blue service.

☆ Elon Musk says Twitter Blue relaunch delayed, may use different color checks for organizations
▼ + stars: | 2022-11-22 | by ( Todd Haselton | ) www.cnbc.com time to read: +2 min

Twitter owner Elon Musk said on Monday evening that the company is planning to delay the relaunch of its $8 per month Blue Verified service. Musk said Twitter will "probably use different color check for organizations than individuals." It allowed users to pay for a Blue checkmark, previously reserved for verified users. Musk had earlier said he planned to relaunch Twitter Blue on Nov. 29. The paid Blue subscription service led to a plethora of pranksters creating imposter accounts on Twitter.

☆ What Cramer is watching Monday — two AMD upgrades, Microsoft hesitancy, Alzheimer's results
▼ + stars: | 2022-11-14 | by ( Jim Cramer | ) www.cnbc.com time to read: +5 min

Baird upgrades Advance Micro Devices (AMD) to outperform from neutral (buy from hold) and raises price target to $100 per share from $65. UBS goes to a buy from neutral as well and raises price target to $95 from $75. Oppenheimer cuts price target on Club holding Nvidia (NVDA) to $225 per share from $250. Credit Suisse analyst Scott Deuschle assumes coverage on Honeywell (HON) with a neutral rating and a $202-per-share price target. Good for Club holding Eli Lily (LLY) and Biogen (BIIB), which are each working on separate experiment treatments for the disease.

☆ Omicron subvariants are resistant to key antibody treatments, putting people with weak immune systems at risk of Covid
▼ + stars: | 2022-10-27 | by ( Spencer Kimball | ) www.cnbc.com time to read: +8 min

Emerging omicron subvariants are resistant to key antibody treatments for HIV patients, kidney transplant recipients and other immunocompromised people, making them particularly vulnerable to Covid this winter, the White House warned this week. While this may be true for the general population, it is not the case for people with weak immune systems. Evusheld is an antibody cocktail authorized by the Food and Drug Administration to prevent Covid in people ages 12 and older who have moderately or severely compromised immune systems. Evusheld, made by AstraZeneca , has helped fill a gap in protection for those with weak immune systems who cannot mount a strong response to the vaccines. Jha acknowledged at the White House on Tuesday that the U.S. has dwindling treatment and prevention options for people with weak immune systems as Covid evolves.

☆ Stocks making the biggest moves midday: Novavax, Darden Restaurants, Eli Lilly and more
▼ + stars: | 2022-09-22 | by ( Jesse Pound | ) www.cnbc.com time to read: +4 min

Darden Restaurants — Shares of Olive Garden's parent company fell more than 4% after Darden's fiscal first-quarter results showed lighter-than-expected revenue. The company reported $1.56 in earnings per share on $2.45 billion of revenue. Eli Lilly — The pharmaceutical stock climbed 4.2% after UBS upgraded Eli Lilly to buy from neutral. KB Home – Shares of homebuilder KB Home slipped 4% after the company reported earnings that disappointed Wall Street's revenue expectations. The company reported $3.13 in adjusted earnings per share, below the $3.20 anticipated by analysts, according to Refinitiv.

Search resuls for: "Eli Lily"

11 mentions found